Applied BioCode Corporation

Taiwan Stock Exchange:6598.TW

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🩺 Medical Instruments

Location

United States

Market Cap

USD 70.18 M

Share Price

USD 0.68

Avg Daily Volume

145,141

Change (1 day)

1.59%

Change (1 year)

-23.70%

Change (YTD)

11.26%

Applied BioCode Corporation EBITDA for the year ending December 31, 2024: USD -6.03 M

Applied BioCode Corporation EBITDA is USD -6.03 M for the year ending December 31, 2024, a 87.71% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Applied BioCode Corporation EBITDA for the year ending December 31, 2023 was USD -3.21 M, a -21.50% change year over year.
Applied BioCode Corporation EBITDA for the year ending December 31, 2022 was USD -4.09 M, a 1.85% change year over year.
Applied BioCode Corporation EBITDA for the year ending December 31, 2021 was USD -4.02 M, a 103.34% change year over year.
Applied BioCode Corporation EBITDA for the year ending December 31, 2020 was USD -1.98 M, a -75.45% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Taiwan Stock Exchange: 6598.TW

Applied BioCode Corporation

CEO	Dr. Winston Z. Ho Ph.D.
IPO Date	Feb. 9, 2017
Location	United States
Headquarters	12130 Mora Dr.
Employees	43
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 🩺 Medical Instruments

Description

Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market. The company's products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. In addition, It develops assays, such as BioCode SARS-CoV-2 Assay, a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; BioCode Respiratory Pathogen Panels, which simultaneously detects and differentiates the presence of 17 respiratory pathogens in nasopharyngeal swabs; BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and MDx assays pipeline for various molecular tests. Further, the company offers fungal pathogen analyte specific reagents; human cytokine/chemokine multiplex kits to identify relevant biomarkers; mouse premixed multiplex kits and custom panels for enhancing flexibility in experimental design allowing the user to pick and choose their own analytes panel; and rat, monkey, canine, and non-human primate cytokine/chemokine multiplex kits. Additionally, the company provides BMB, calibration beads, and coupling kits for various bioassay applications; ELISA, a tool for the quantitative measurement of drug/protein/antibody levels in biological samples comprising cell lysate or serum; and various assay development services. Applied BioCode Corporation is based in Santa Fe Springs, California.